According to a study presented at the 2021 Scientific Sessions of the American Heart Association. The researchers found that this improvement was especially pronounced in patients with higher levels of inflammation. The hospitalization rate has not been reduced.
“Cell therapy has the potential to change the way we treat heart failure,” said Emerson C. Perin, MD, PhD, director of the Center for Clinical Research and medical director of the Texas Heart Institute in Houston, in a statement. Press. “This study focuses on the inflammatory aspects of heart failure, which for the most part go untreated, despite the significant development of pharmaceutical therapy and devices. Our results indicate that stem cell therapy can be considered for use in addition to standard therapies.
In the DREAM-HF trial, investigators recruited 537 participants with HFrEF and randomized these patients into 2 groups. The first received an injection of 150 million mesenchymal precursor cells, commonly known as stem cells, directly into the heart using a catheter, while the second group received a scripted sham procedure. The mesenchymal precursor cells were provided by healthy adult donors.
According to investigators, participants who received stem cell therapy had a 65% reduction in non-fatal heart attacks and strokes throughout the study period. Additionally, patients with high levels of inflammation were 79% less likely to have a heart attack or non-fatal stroke after being treated with stem cells, and their risk of cardiac death was reduced by 80%. if they had class 2 heart failure.
“We were impressed to learn that the effects of stem cell therapy were in addition to current standard treatments for heart failure,” said Perin. “For the first time, the known anti-inflammatory mechanism of action of these cells may be linked to a cause-and-effect benefit in heart failure. Stem cells worked locally in the heart, and they also helped blood vessels throughout the body. “
The researchers said more research is needed to understand the influence of stem cells on the course of heart failure and how these therapies should be directed to reach the groups of patients who could benefit the most from them.
Stem cell therapy for heart failure reduced major CV events and deaths, not hospitalizations [news release]. EurekAlert; November 15, 2021. Accessed November 16, 2021. https://www.eurekalert.org/news-releases/934870